Info Antisoma - 500 Beiträge pro Seite

[eisbaer24]

Antisoma

Company Description
Antisoma Plc is a biopharmaceutical company specialising in the pre-clinical and clinical development of products for the treatment of cancer.It operates laboratories in Great Britain, whereby it focuses on clinical studies towards the development of innovative tumour targeting products based on monoclonal antibody or peptide vectors. The company became listed on EASDAQ on 17 December 1998. During the year, the company successfully licensed its lead product candidate, Theragyn, to Abbott Laboratories ("Abbott"), and adopted a new product, Therex, into clinical development.
Competitor Analysis
Antisoma Plc operates in the Medical Services sub-industry, which is a subsector of the Miscellaneous industry. This analysis compares Antisoma Plc with three other companies in the same sub industry in Western Europe: Isotron PLC (2000 sales of £14.45 million [US$20.91 million] ), Unilabs AG of Switzerland (164.20 million Swiss Francs [US$92.56 million] ), and Trinity Care Plc (£21.96 million [US$31.77 million] of which 100% was Nursing homes).
Sales Analysis
Sales increased substantially in 2000: Antisoma Plc reported sales of £1.54 million (US$2.23 million) for the fiscal year ending June of 2000. This represents an increase of 2,629.0% versus 1999, when the company`s sales were £56,540.00 .
During 2000, the company`s sales increased at a faster rate than all three comparable companies. While Antisoma Plc enjoyed a sales increase of 2,629.0%, the other companies saw smaller increases: Isotron PLC sales were up 4.8%, Unilabs AG increased 15.7%, and Trinity Care Plc experienced growth of 24.5%.
Antisoma Plc currently has 28 employees. With sales of £1.54 million (US$2.23 million) , this equates to sales of US$79,750 per employee.
Sales Comparisons (Fiscal Year ending 2000)
Company YearEnded Sales(US$mlns) SalesGrowth Sales/Emp (US$) Largest Region
Antisoma Plc Jun 2000 2.233 2,629.0% 79,750 N/A
Isotron PLC Jun 2000 20.906 4.8% 114,240 N/A
Unilabs AG May 2000 92.560 15.7% 108,894 N/A
Trinity Care Plc Mar 2000 31.774 24.5% 21,311 N/A


The stock price has more than doubled recently: For the 52 weeks ending 10/13/00, the stock of this company was up 228.3% to 174.00 p. During the past 13 weeks, the stock has increased 20.8%.
During the 12 months ending 6/30/00, the company has experienced losses totalling 11.00 p per share. These 12 month earnings are lower than the earnings per share achieved during the last fiscal year of the company, which ended in June of 2000, when the company reported earnings of -10.60 p per share.
This company is currently trading at 87.57 times sales. This is at a much higher ratio than all three comparable companies, which are trading between 0.25 and 4.27 times sales. This company has negative book value (and thus a price to book value would not make any sense).
Summary of company valuations
Company Date P/E Price/Book Price/Sales 52 WkPr Chg
Antisoma Plc 10/13/00 N/A N/A 87.57 228.30%
Isotron PLC 10/12/00 18.2 2.09 4.27 -1.03%
Unilabs AG 10/13/00 37.2 7.85 3.65 238.06%
Trinity Care Plc 9/29/00 6.4 0.45 0.25 -28.10%
The market capitalization of this company is £135.12 million (US$195.54 million) . The capitalization of the floating stock (i.e., that which is not closely held) is £101.02 million (US$146.19 million) .
Dividend Analysis
This company has paid no dividends during the last 12 months. The company also reported losses during the previous 12 months. The three comparable companies all paid dividends during the previous 12 months, however. The company has not paid any dividends during the previous 2 fiscal years.
Profitability Analysis
The company`s earnings before interest, taxes, depreciation and amorization (EBITDA) were -£7.88 million, or -510.4% of sales. This EBITDA margin is worse than the company achieved in 1999, when the EBITDA margin was equal to 100.0% of sales.
In 2000, earnings before extraordinary items at Antisoma Plc were -£7.92 million, or -513.2% of sales. This profit margin is lower than the level the company achieved in 1999, when the profit margin was 11,287.1% of sales.
The company`s return on equity in 2000 was -230.8%. This was significantly worse than the already high 509.6% return the company achieved in 1999. (Extraordinary items have been excluded).
During the third quarter of 2000, Antisoma Plc reported a loss per share of £0.09.
Research and Development
Research and Development Expenses at Antisoma Plc in 2000 were £6.47 million, which is equivalent to 419.4% of sales.
Financial Position
At the end of 2000, the company had negative common shareholder`s equity of -£796,000.00 . This means that at the present time, the common shareholders have essentially no equity in the company. Although the common equity is negative, Antisoma Plc does have a net positive equity position (as its preferred stock, minority interest, etc. are positive).
As of June 2000, the company`s long term debt was £19,000.00 and total liabilities (i.e., all monies owed) were £2.58 million. The long term debt to equity ratio of the company is very low, at only 0.01.
This company has a large cash balance: in 2000, the company had only £1.54 million in sales, but its cash and short term investments as of June 2000 were £4.42 million, or 2.9 times the annual sales.
Antisoma Plc does not appear to be very efficient in collecting payments: As of June 2000, the accounts receivable for the company were £1.02 million, which is equivalent to 241 days of sales. This is an improvement over the end of 1999, when Antisoma Plc had 620 days of sales in accounts receivable

[Guerilla Investor]

Hi !

Es wäre schön, immer auch ein kurzes Statement in deutsch zu bekommen, für die nur Deutschkönner ... *g
Generell wünschenswert, so verpufft die halbe Wirkung ...

Gruß Guerilla

Unter folgendem Link gibt es erste Infos für eine
angestrebte Neugründung. Thread: BERLIN - Guerill@ Investment Club

[Millenium-Bug]

so langsam wächst das Handelsvolumen bei Antisoma an, heute schon gegen Mittag fast das Handelsvolumen von gestern eingestellt. Das läßt hoffen

Gruß
Bug

[menatwork00]

Stimmt hervorragendes Handelsvolume und bis jetzt 12.00 wieder 5,48 %
zu gestern gestiegen. OH yes what a deal !!!


Gruß MH

[Stockguru]

ANTISOMA ist in England bereits so etwas wie der Liebling der Börse !

ANTISOMA wird ein verfielfacher werden !


KZ Ende Dieses Jahres 6 Euro !!!

[Stockguru]

ANTISOMA ist in England bereits so etwas wie der Liebling der Börse !

ANTISOMA wird ein verfielfacher werden !


KZ Ende Dieses Jahres 6 Euro !!!

[Stockguru]

ANTISOMA ist in England bereits so etwas wie der Liebling der Börse !

ANTISOMA wird ein verfielfacher werden !


KZ Ende Dieses Jahres 6 Euro !!!

[Hajo3]

Info
Hier der aktuelle positive Stand:

ANTISOMA ORD 1P
London Inl. 5569603 215,00 +20,00 +10,26% 47,91 Mio. 13:27/19.10.
London 5569603 213,50 +17,50 +8,93% 48,25 Mio. 13:11/19.10.
ANTISOMA PLC SHARES LS -, 01
Frankfurt 917990 3,88 +0,23 +6,30% 893.286,80 13:26/19.10.
München 917990 3,85 +0,30 +8,45% 35.381,70 13:21/19.10.
Berlin 917990 3,88 +0,23 +6,30% 117.835,40 13:25/19.10.
Stuttgart 917990 3,88 +0,23 +6,30% 35.700,30 12:53/19


Was schreibt der "Der Aktionär" in seiner heutigen Auflagen??
Nachrichten werden folgen.

Gruß Hajo

[epicuraul]